Last reviewed · How we verify
NCT03537235: ELOT
Evaluation of Libramed in Obesity Treatment
NA trial testing Libramed in Overweight and Obesity in 40 participants. Completed in 22 February 2019.
22 February 2019
Quick facts
| Lead sponsor | Aboca Spa Societa' Agricola |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 29 June 2015 |
| Primary completion | 22 February 2019 |
| Estimated completion | 22 February 2019 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Libramed — full drug profile →
- Placebo
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Aboca Spa Societa' Agricola — full company profile →
Who can join
Adults 20 to 35, female only, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized, double-blind, placebo-controlled study aimed at evaluating the effects of a 3-months treatment with Policaptil Gel Retard on postprandial incretin hormones release and satiety in obese women
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03537235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Libramed
Trials testing the same drug.
- NCT03423368 — Policaptil Gel Retard® in Overweight and Mild Obese Subjects · NA · completed
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Aboca Spa Societa' Agricola trials
Trials by the same sponsor.
- NCT05904938 — Oral Administration of Actitan-F in Paediatric Diarrhoea · NA · unknown
- NCT05192317 — Administration of a Natural Molecular Complex in Functional Chronic Constipation · NA · unknown
- NCT05016024 — Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome. · NA · completed
- NCT03531372 — Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn. · NA · completed
- NCT03545724 — Effectiveness & Safety of Neofitoroid® in Hemorrhoidal Disease · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03537235 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aboca Spa Societa' Agricola
- Last refreshed: 30 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03537235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing